Multiparametric MRI and Radiomics to Predict HER2-Low Cancer: The Potential Therapeutic Impact

HomeRadiologyVol. 308, No. 2 PreviousNext Reviews and CommentaryEditorialMultiparametric MRI and Radiomics to Predict HER2-Low Cancer: The Potential Therapeutic ImpactMasako Kataoka , Maya HondaMasako Kataoka , Maya HondaAuthor AffiliationsFrom the Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin-kawaharacho Sakyo-ku, Kyoto 606-8507 Japan (M.K.); and Department of Diagnostic Radiology, Kansai Electric Power Hospital, Osaka, Japan (M.H.).Address correspondence to M.K. (email: [email protected]).Masako Kataoka Maya HondaPublished Online:Aug 1 2023https://doi.org/10.1148/radiol.231649MoreSectionsFull textPDF ToolsAdd to favoritesCiteTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinked In References1. Modi S, Jacot W, Yamashita T, et al; DESTINY-Breast04 Trial Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 2022;387(1):9–20. Crossref, Medline, Google Scholar2. Moy B, Rumble RB, Carey LA; Chemotherapy and Targeted Therapy for HER2-Negative Metastatic Breast Cancer that is Either Endocrine-Pretreated or Hormone Receptor–Negative Expert Panel. Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 2022;40(26):3088–3090. Crossref, Medline, Google Scholar3. de Nonneville A, Houvenaeghel G, Cohen M, et al. Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers. Eur J Cancer 2022;176:181–188. Crossref, Medline, Google Scholar4. Hu XE, Yang P, Chen S, et al. Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low. Breast Cancer Res 2023;25(1):34. Crossref, Medline, Google Scholar5. Ramtohul T, Djerroudi L, Lissavalid Eea, et al. Multiparametric MRI and radiomics for the prediction of HER2-zero, -low and -positive breast cancers. Radiology 2023;308(2);e222646. Link, Google Scholar6. Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images Are More than Pictures, They Are Data. Radiology 2016;278(2):563–577. Link, Google Scholar7. Bian X, Du S, Yue Z, et al. Potential Antihuman Epidermal Growth Factor Receptor 2 Target Therapy Beneficiaries: The Role of MRI-Based Radiomics in Distinguishing Human Epidermal Growth Factor Receptor 2-Low Status of Breast Cancer. J Magn Reson Imaging 2023. https://doi.org/10.1002/jmri.28628. Published online February 10, 2023. Crossref, Google Scholar8. Romeo V, Helbich TH, Pinker K. Breast PET/MRI Hybrid Imaging and Targeted Tracers. J Magn Reson Imaging 2023;57(2):370–386. Crossref, Medline, Google Scholar9. Iima M, Honda M, Sigmund EE, Ohno Kishimoto A, Kataoka M, Togashi K. Diffusion MRI of the breast: Current status and future directions. J Magn Reson Imaging 2020;52(1):70–90. Crossref, Medline, Google Scholar10. Pinker K, Chin J, Melsaether AN, Morris EA, Moy L. Precision Medicine and Radiogenomics in Breast Cancer: New Approaches toward Diagnosis and Treatment. Radiology 2018;287(3):732–747. Link, Google ScholarArticle HistoryReceived: June 27 2023Revision requested: June 30 2023Revision received: July 3 2023Accepted: July 6 2023Published online: Aug 01 2023 FiguresReferencesRelatedDetailsAccompanying This ArticleMultiparametric MRI and Radiomics for the Prediction of HER2-Zero, -Low, and -Positive Breast CancersAug 1 2023RadiologyRecommended Articles Change Is Good: The Evolution and Future of Breast ImagingRadiology2023Volume: 306Issue: 3Breast Parenchymal Enhancement as a Predictor of Efficacy for Endocrine TherapyRadiology2023Volume: 307Issue: 4The Contribution of Imaging as a Prognostic Marker of Luminal Breast CancerRadiology2022Volume: 304Issue: 2pp. 320-321Precision Medicine and Radiogenomics in Breast Cancer: New Approaches toward Diagnosis and TreatmentRadiology2018Volume: 287Issue: 3pp. 732-747Features from Computerized Texture Analysis of Breast Cancers at Pretreatment MR Imaging Are Associated with Response to Neoadjuvant ChemotherapyRadiology2017Volume: 286Issue: 2pp. 412-420See More RSNA Education Exhibits Theranostic Approach In Breast CancerDigital Posters2021Breast Density Included in the Modern Rules of Mammographic ScreeningDigital Posters2019Evolving Role of Nuclear Medicine and Molecular Imaging in Breast Cancer - A Case-based Multi-modality Pictorial Review with Teaching PearlsDigital Posters2022 RSNA Case Collection Occult Breast CancerRSNA Case Collection2022Secondary Angiosarcoma of the BreastRSNA Case Collection2021Multifocal breast cancerRSNA Case Collection2020 Vol. 308, No. 2 Metrics Altmetric Score PDF download